Biotest Aktiengesellschaft (BIESF)
USD 32.0
(0.0%)
USD 32.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.41 Billion EUR | 17.28% |
| 2022 | 1.2 Billion EUR | 8.95% |
| 2021 | 1.1 Billion EUR | -2.4% |
| 2020 | 1.13 Billion EUR | 2.07% |
| 2019 | 1.1 Billion EUR | 6.34% |
| 2018 | 1.04 Billion EUR | 6.52% |
| 2017 | 978.5 Million EUR | 4.9% |
| 2016 | 932.8 Million EUR | -3.11% |
| 2015 | 962.7 Million EUR | -6.77% |
| 2014 | 1.03 Billion EUR | 16.48% |
| 2013 | 886.5 Million EUR | 29.92% |
| 2012 | 682.34 Million EUR | -0.06% |
| 2011 | 682.76 Million EUR | 7.97% |
| 2010 | 632.33 Million EUR | -0.18% |
| 2009 | 633.45 Million EUR | 6.99% |
| 2008 | 592.04 Million EUR | 10.31% |
| 2007 | 536.7 Million EUR | 48.24% |
| 2006 | 362.05 Million EUR | 3.15% |
| 2005 | 351.01 Million EUR | -2.03% |
| 2004 | 358.27 Million EUR | 2.37% |
| 2003 | 349.97 Million EUR | -5.92% |
| 2002 | 371.99 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.37 Billion EUR | -4.91% |
| 2024 Q1 | 1.44 Billion EUR | 2.54% |
| 2023 Q2 | 1.21 Billion EUR | 2.01% |
| 2023 Q3 | 1.34 Billion EUR | 11.15% |
| 2023 FY | 1.41 Billion EUR | 17.28% |
| 2023 Q4 | 1.41 Billion EUR | 4.55% |
| 2023 Q1 | 1.19 Billion EUR | -1.06% |
| 2022 FY | 1.2 Billion EUR | 8.95% |
| 2022 Q3 | 1.07 Billion EUR | -2.05% |
| 2022 Q2 | 1.1 Billion EUR | -0.71% |
| 2022 Q4 | 1.2 Billion EUR | 11.46% |
| 2022 Q1 | 1.1 Billion EUR | 0.51% |
| 2021 Q1 | 1.13 Billion EUR | 0.31% |
| 2021 FY | 1.1 Billion EUR | -2.4% |
| 2021 Q2 | 1.14 Billion EUR | 0.97% |
| 2021 Q3 | 1.13 Billion EUR | -0.91% |
| 2021 Q4 | 1.1 Billion EUR | -2.75% |
| 2020 Q2 | 1.14 Billion EUR | 3.39% |
| 2020 Q1 | 1.1 Billion EUR | -0.07% |
| 2020 Q3 | 1.12 Billion EUR | -2.01% |
| 2020 Q4 | 1.13 Billion EUR | 0.81% |
| 2020 FY | 1.13 Billion EUR | 2.07% |
| 2019 Q2 | 1.05 Billion EUR | 1.3% |
| 2019 FY | 1.1 Billion EUR | 6.34% |
| 2019 Q4 | 1.1 Billion EUR | 1.59% |
| 2019 Q3 | 1.09 Billion EUR | 3.1% |
| 2019 Q1 | 1.04 Billion EUR | 0.22% |
| 2018 FY | 1.04 Billion EUR | 6.52% |
| 2018 Q4 | 1.04 Billion EUR | -0.5% |
| 2018 Q2 | 1.33 Billion EUR | 31.23% |
| 2018 Q1 | 1.01 Billion EUR | 3.96% |
| 2018 Q3 | 1.04 Billion EUR | -21.53% |
| 2017 Q3 | 953.6 Million EUR | -1.4% |
| 2017 Q2 | 967.1 Million EUR | 8.76% |
| 2017 Q4 | 978.5 Million EUR | 2.61% |
| 2017 Q1 | 889.2 Million EUR | -4.67% |
| 2017 FY | 978.5 Million EUR | 4.9% |
| 2016 Q1 | 968.3 Million EUR | 0.58% |
| 2016 Q3 | 962.4 Million EUR | -1.99% |
| 2016 FY | 932.8 Million EUR | -3.11% |
| 2016 Q4 | 932.8 Million EUR | -3.08% |
| 2016 Q2 | 981.9 Million EUR | 1.4% |
| 2015 Q3 | 962.8 Million EUR | -8.5% |
| 2015 FY | 962.7 Million EUR | -6.77% |
| 2015 Q4 | 962.7 Million EUR | -0.01% |
| 2015 Q2 | 1.05 Billion EUR | -1.87% |
| 2015 Q1 | 1.07 Billion EUR | 3.83% |
| 2014 Q2 | 914.3 Million EUR | 1.31% |
| 2014 Q3 | 932.1 Million EUR | 1.95% |
| 2014 Q4 | 1.03 Billion EUR | 10.78% |
| 2014 FY | 1.03 Billion EUR | 16.48% |
| 2014 Q1 | 902.5 Million EUR | 1.8% |
| 2013 Q3 | 746.5 Million EUR | 0.09% |
| 2013 Q4 | 886.5 Million EUR | 18.75% |
| 2013 FY | 886.5 Million EUR | 29.92% |
| 2013 Q1 | 663.8 Million EUR | -2.72% |
| 2013 Q2 | 745.8 Million EUR | 12.35% |
| 2012 FY | 682.34 Million EUR | -0.06% |
| 2012 Q3 | 672.8 Million EUR | -2.24% |
| 2012 Q4 | 682.34 Million EUR | 1.42% |
| 2012 Q1 | 689.5 Million EUR | 0.99% |
| 2012 Q2 | 688.2 Million EUR | -0.19% |
| 2011 Q1 | 637.9 Million EUR | 0.88% |
| 2011 Q4 | 682.76 Million EUR | -5.42% |
| 2011 FY | 682.76 Million EUR | 7.97% |
| 2011 Q2 | 680.8 Million EUR | 6.73% |
| 2011 Q3 | 721.9 Million EUR | 6.04% |
| 2010 Q4 | 632.33 Million EUR | -1.27% |
| 2010 Q3 | 640.5 Million EUR | -2.38% |
| 2010 Q2 | 656.1 Million EUR | 3.01% |
| 2010 FY | 632.33 Million EUR | -0.18% |
| 2010 Q1 | 636.9 Million EUR | 0.54% |
| 2009 FY | 633.45 Million EUR | 6.99% |
| 2009 Q4 | 633.45 Million EUR | 0.0% |
| 2008 FY | 592.04 Million EUR | 10.31% |
| 2007 FY | 536.7 Million EUR | 48.24% |
| 2006 FY | 362.05 Million EUR | 3.15% |
| 2005 FY | 351.01 Million EUR | -2.03% |
| 2004 FY | 358.27 Million EUR | 2.37% |
| 2003 FY | 349.97 Million EUR | -5.92% |
| 2002 FY | 371.99 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Bioxytran, Inc. | 137.63 Thousand USD | -1024980.283% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -3531.941% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -1847740.323% |
| SQZ Biotechnologies Company | 107.18 Million USD | -1216.298% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -98424.335% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -13268.391% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -983.551% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -1949599.44% |
| Marizyme, Inc. | 22.01 Million USD | -6308.79% |
| Genus plc | 1.02 Billion USD | -37.127% |
| Pharming Group N.V. | 462.85 Million USD | -204.826% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -42486.625% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -282623.394% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -224923.923% |
| ContraFect Corporation | 20.67 Million USD | -6722.864% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -369074.492% |
| IMV Inc. | 31.33 Million USD | -4402.807% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -33930.21% |
| ONE Bio Corp. | 70.08 Million USD | -1913.112% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -997.891% |
| Mesoblast Limited | 667.9 Million USD | -111.244% |
| MultiCell Technologies, Inc. | 126.22 USD | -1117810072.714% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -3910.631% |
| Genscript Biotech Corporation | 3.38 Billion USD | 58.336% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -182980.644% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -539901.607% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -19442.195% |
| Biomind Labs Inc. | 73.81 Thousand USD | -1911196.55% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -97281.152% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -4600.657% |
| Skye Bioscience, Inc. | 11.94 Million USD | -11716.176% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -103768.435% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -51273.922% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -361330.043% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -71951.268% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -205125.997% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -150045.42% |
| EV Biologics, Inc. | 431.71 Thousand USD | -326713.585% |
| Q BioMed Inc. | 3.51 Million USD | -40033.5% |
| GB Sciences, Inc. | 103.44 Thousand USD | -1363852.746% |
| Alpha Cognition Inc. | 2.45 Million USD | -57436.794% |
| CSL Limited | 38.02 Billion USD | 96.289% |
| Agentix Corp. | 261.39 Thousand USD | -539664.033% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | -216.126% |
| Enzolytics Inc. | 361.7 Million USD | -290.068% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 8.11 Million USD | -17286.322% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -75032.596% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -54098.762% |
| argenx SE | 4.54 Billion USD | 68.94% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -4949.027% |
| HST Global, Inc. | 1526.00 USD | -92457304.98% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -2857.738% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -142708.414% |
| Halberd Corporation | 10.13 Thousand USD | -13926462.037% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -220471.682% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -15665.734% |
| Zenith Capital Corp. | 7410.00 USD | -19040385.83% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -6193218.994% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -438331.85% |
| AVAX Technologies, Inc. | 7.37 Million USD | -19025.254% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -539721.858% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -151943.028% |
| Ember Therapeutics, Inc. | 184.00 USD | -766793378.261% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 62.24 Thousand USD | -2266478.846% |
| Helix BioMedix, Inc. | 3.02 Million USD | -46539.996% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -2577.179% |
| Kadimastem Ltd | 2.3 Million USD | -61134.853% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -9590.054% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -2471087.866% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -61077822.078% |
| LadRx Corporation | 2.3 Million USD | -61033.975% |
| Cell Source, Inc. | 195.17 Thousand USD | -722804.53% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -293496.805% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -398890.999% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -398890.999% |
| Affymax, Inc. | 7.44 Million USD | -18856.066% |
| Mobile Lads Corp. | 52.00 USD | -2713269130.769% |
| Itoco Inc. | 1.4 Million USD | -100673.389% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -1474857.4% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -1330937.736% |
| International Stem Cell Corporation | 5.39 Million USD | -26076.252% |
| CytoDyn Inc. | 11.13 Million USD | -12569.72% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -986736.583% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -7890839.597% |
| Qrons Inc. | 420.00 USD | -335928471.429% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -365919.752% |
| SYBLEU INC | 330.46 Thousand USD | -426839.976% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -255442.273% |
| Rebus Holdings, Inc. | 5000.00 USD | -28217900.0% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -344507.764% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -9304.853% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -8410.163% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -1785849.367% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -163070.756% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -18669.456% |
| Neutra Corp. | 2851.00 USD | -49487798.983% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -4253.823% |
| PureTech Health plc | 693.97 Million USD | -103.308% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -17380.912% |
| IXICO plc | 15.84 Million USD | -8805.003% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -16935.74% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -1265.51% |
| CSL Limited | 38.02 Billion USD | 96.289% |
| Cellectis S.A. | 333.99 Million USD | -322.432% |